|
|
Article: MetaPhore's $30M Financing To Push Packaged Enzymes'.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With $30 million in hand from a Series C financing, MetaPhore Pharmaceuticals Inc. said it plans to have one of its superoxide dismutase (SOD) mimetics in a second Phase II trial this year, and another from the class entering Phase II next year.
"We have about $31 million in cash [with the financing], and we believe that will take us to initial proof of human efficacy," said Constantine Anagnostopoulos, chairman of St. Louis-based MetaPhore. "Timewise, that's well into 2004."
MetaPhore's lead SOD mimetics are M40403 and M40419. M40403 is in Phase II trials for refractory hypotension and scheduled to enter Phase II studies for ...